These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment. Grieco T; Dies L; Sernicola A; Chello C; Gagliostro N; Carnicelli G; Paolino G Immunotherapy; 2020 Nov; 12(16):1173-1181. PubMed ID: 32892673 [No Abstract] [Full Text] [Related]
50. Effect of omalizumab treatment on peripheral nerves in patients with chronic spontaneous urticaria. Altunisik E; Inan Dogan E Cutan Ocul Toxicol; 2021 Jun; 40(2):130-134. PubMed ID: 33902373 [No Abstract] [Full Text] [Related]
51. Omalizumab in chronic inducible urticaria: A retrospective, real-life study. Fialek M; Dezoteux F; Le Moing A; Karimova E; Ramdane N; Pape E; Azib-Meftah S; Staumont-Sallé D Ann Dermatol Venereol; 2021 Dec; 148(4):262-265. PubMed ID: 34247853 [No Abstract] [Full Text] [Related]
52. Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy. Liao SL; Yu M; Zhao ZT; Maurer M Front Immunol; 2021; 12():652973. PubMed ID: 33796115 [TBL] [Abstract][Full Text] [Related]
53. Efficacy of additional treatment for chronic spontaneous urticaria refractory to treatment - A single-center retrospective real-world study. Ohata M; Oda Y; Washio K; Fukunaga A; Nishigori C J Dermatol; 2022 Jan; 49(1):e7-e8. PubMed ID: 34632611 [No Abstract] [Full Text] [Related]
54. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720 [TBL] [Abstract][Full Text] [Related]
55. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?]. Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084 [No Abstract] [Full Text] [Related]
56. Use of omalizumab in the treatment of chronic urticaria. Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430 [TBL] [Abstract][Full Text] [Related]
57. Factors related to omalizumab resistance in chronic spontaneous urticaria. Magen E; Chikovani T; Waitman DA; Kahan NR Allergy Asthma Proc; 2019 Jul; 40(4):273-278. PubMed ID: 31262381 [No Abstract] [Full Text] [Related]
58. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders? Asero R Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398 [No Abstract] [Full Text] [Related]